William Blair reaffirmed their outperform rating on shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in a research report sent to investors on Monday. William Blair also issued estimates for Sarepta Therapeutics’ Q4 2018 earnings at ($0.39) EPS.

Several other brokerages have also commented on SRPT. Leerink Swann reiterated an outperform rating and issued a $66.00 price target on shares of Sarepta Therapeutics in a research note on Saturday. Instinet restated a buy rating and set a $84.00 price objective on shares of Sarepta Therapeutics in a research report on Monday. J P Morgan Chase & Co restated a hold rating on shares of Sarepta Therapeutics in a research report on Monday, September 25th. Robert W. Baird restated an outperform rating and issued a $101.00 target price on shares of Sarepta Therapeutics in a report on Monday. Finally, Credit Suisse Group restated an outperform rating and issued a $81.00 target price on shares of Sarepta Therapeutics in a report on Monday. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have given a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $62.79.

Sarepta Therapeutics (NASDAQ SRPT) opened at 49.55 on Monday. The firm’s market cap is $3.19 billion. The firm’s 50-day moving average is $42.14 and its 200-day moving average is $35.85. Sarepta Therapeutics has a 52 week low of $26.26 and a 52 week high of $63.03.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million for the quarter, compared to analysts’ expectations of $22.52 million. Sarepta Therapeutics’s revenue for the quarter was up 350000.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.19) EPS. On average, equities analysts anticipate that Sarepta Therapeutics will post ($1.22) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Sarepta Therapeutics, Inc. (SRPT) Given “Outperform” Rating at William Blair” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/10/03/sarepta-therapeutics-inc-srpt-given-outperform-rating-at-william-blair.html.

In related news, Director Edward M. Md Kaye sold 10,000 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $410,000.00. Following the sale, the director now directly owns 62,471 shares in the company, valued at $2,561,311. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Shamim Ruff sold 12,138 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $42.97, for a total value of $521,569.86. Following the completion of the sale, the senior vice president now owns 27,312 shares in the company, valued at $1,173,596.64. The disclosure for this sale can be found here. Over the last three months, insiders have sold 78,056 shares of company stock valued at $3,224,208. Company insiders own 9.60% of the company’s stock.

Large investors have recently added to or reduced their stakes in the business. Prentiss Smith & Co. Inc. raised its position in Sarepta Therapeutics by 772.2% in the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 3,166 shares in the last quarter. Ameritas Investment Partners Inc. purchased a new stake in shares of Sarepta Therapeutics during the 1st quarter worth $127,000. PNC Financial Services Group Inc. boosted its position in shares of Sarepta Therapeutics by 150.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock worth $138,000 after purchasing an additional 2,800 shares in the last quarter. Cubist Systematic Strategies LLC boosted its position in shares of Sarepta Therapeutics by 116.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 2,474 shares in the last quarter. Finally, Edge Wealth Management LLC purchased a new stake in shares of Sarepta Therapeutics during the 2nd quarter worth $175,000. Hedge funds and other institutional investors own 65.41% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.